KMKeiji Miyazawa

Keiji Miyazawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Keiji Miyazawa has a total of 147 co-authors. Here are the top co-authors by number of shared publications:

  • Masao Saitoh

    Department of Biochemistry, Graduate School of Medicine, University of Yamanashi , 1110 Shimokato, Chuo , Yamanashi 409-3898

    11 shared publications
  • Yuka Itoh

    Department of Biochemistry, Graduate School of Medicine, University of Yamanashi , 1110 Shimokato, Chuo , Yamanashi 409-3898

    9 shared publications
  • Masao Saitoh

    Department of Biochemistry Graduate School of Medicine, University of Yamanashi Chuo Japan

    7 shared publications
  • Chiho Omata

    Department of Biochemistry, Graduate School of Medicine University of Yamanashi Chuo Japan

    6 shared publications
  • Mitsuyoshi Motizuki

    Department of Biochemistry and Sciences, Graduate School of Medicine, University of Yamanashi, Yamanashi 409-3898, Japan

    5 shared publications
  • Daizo Koinuma

    The Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan

    3 shared publications

Latest Publications

  • TGF-β downregulates E-cadherin expression via a novel ZEB1-dependent mechanism

    by Shigeo Otake, Yuka Itoh, Masao Saitoh, Keiji Miyazawa

    Zinc finger E-box-binding homeobox 1 (ZEB1) is a core transcription factor regulating epithelial–mesenchymal transition (EMT) and its high expression is associated with malignant cancer phenotypes and poor prognosis. ZEB1 mediates the downregulation of E-cadherin (encoded by CDH1) as a hallmark of cells undergoing EMT. We previously identified two distinct modes of E-cadherin downregulation by ZEB1, namely basal repression and stimulus-dependent repression. The current study aimed to investigate the mechanisms responsible for stimulus-dependent repression induced by transforming growth factor-β (TGF-β) using ZEB1-knockout cells. Knockout of ZEB1 resulted in upregulation of basal E-cadherin expression and attenuation of its downregulation following TGF-β treatment. TGF-β-induced E-cadherin downregulation required Smad3 signalling, but did not involve upregulation of ZEB1 expression, suggesting functional modulation of ZEB1. C-terminal binding proteins were required for basal repression but not for TGF-β-induced downregulation. Consistently, basal repression of CDH1 by ZEB1, but not TGF-β-induced downregulation, was associated with histone deacetylation in the CDH1 regulatory regions; however, both processes required histone deacetylase activity. Histone deacetylase may therefore play a role in regulating the expression or function of factor(s) required for TGF-β-induced CDH1 downregulation. These results suggest that TGF-β downregulates E-cadherin expression via a novel ZEB1-dependent mechanism.


  • Open Access

    TGFβ signaling promotes cell cycle progression and resistance to the CDK4/6 inhibitor palbociclib through SOX4 transcriptional modulation in breast cancer cells

    by Mohamad Moustafa Ali, Yuka Itoh, Aisha Mariama Pereira Badji, Sarah Gallant, Chrysoula Tsirigoti, Yu Bai, Beata Filipek-Górniok, Keiji Miyazawa, Carl-Henrik Heldin, Aristidis Moustakas

    Cancer signaling encompasses a wide array of entangled molecular cascades that promote oncogenic progression and counteract the effect of tumor suppressors. Transforming growth factor β (TGFβ) induces complex and stage-dependent effects throughout tumor progression. During pre-malignant hyperplastic growth, TGFβ restricts cell proliferation and inflammation, while on the other hand, TGFβ promotes migration and distal metastasis of cancer cells. To dissect the temporal chromatin-based transcriptional response to TGFβ, we employed 3D culture models of isogenic human breast epithelial cells, exemplified by non-oncogenic MCF-10A (MI) and their HRAS-transformed counterpart (MII). Genome-wide chromatin accessibility profiling revealed an extensive chromatin opening induced by TGFβ at transcription start sites and enhancer elements in both models, with a marked enrichment of SOX4 binding motifs in oncogenic cells. Transcriptomic analyses unexpectedly revealed the upregulation of DNA replication and DNA damage response pathways, following TGFβ stimulation of oncogenic MII 3D cultures. Canonical TGFβ-driven programs, including epithelial-mesenchymal transition and metabolic reprogramming, were activated in both models. Notably, single-cell RNA-seq of primary breast tumors confirmed co-expression of SOX4 and cell cycle regulators. Mechanistically, we show that TGFβ induces the interaction between the MH2 domain of SMAD3 and the intrinsically disordered regions of SOX4, co-activating downstream gene targets. Validating the genome-wide analyses, we found that resistance of breast cancer cells to the CDK4/6 inhibitor palbociclib conferred by TGFβ stimulation was functionally dependent on SOX4. Collectively, our findings reveal an apparent oncogenic function of TGFβ in promoting cell cycle progression and drug resistance through SOX4, highlighting the pro-tumorigenic role of TGFβ signaling in breast cancer progression.


  • Open Access

    TGF‐β Enhances Doxorubicin Resistance and Anchorage‐Independent Growth in Cancer Cells by Inducing ALDH1A1 Expression

    by Takashi Yokoyama, Masao Saitoh, Keiji Miyazawa

    The transforming growth factor‐β (TGF‐β)/Smad signaling pathway promotes malignant transformation through various mechanisms, and its effect on enhancing drug resistance can limit the efficacy of treatment. Here, we showed that pre‐stimulation of human lung cancer A549 cells with TGF‐β increases resistance to doxorubicin‐induced growth inhibition in a Smad3‐ and Smad4‐dependent manner. This effect was suppressed by the aldehyde dehydrogenase (ALDH) inhibitor oxyfedrine, suggesting that ALDH family members are involved in drug resistance. TGF‐β upregulated the mRNA and protein expression of ALDH1A1. The TGF‐β/Smad3 transcriptional enhancer region on ALDH1A1 was identified by Smad3 ChIP‐seq analysis using an open database and by reporter assays. Knockdown of ALDH1A1 in A549 cells suppressed TGF‐β–induced doxorubicin resistance, and lentivirus‐mediated introduction of ALDH1A1 into A549 SMAD3‐KO cells restored drug resistance. We also demonstrated that ALDH1A1 is required and sufficient for TGF‐β/Smad3 signaling–induced anchorage‐independent growth. The results suggest that the TGF‐β/Smad3/4 axis promotes resistance to doxorubicin and anchorage‐independent growth by inducing the transcription of ALDH1A1.


  • Open Access

    Identification of a Distal Enhancer That Regulates TGF‐β–Induced SNAI1 Expression

    by Hao Fu, Yuka Itoh, Tomoe Sawaguchi, Shigeo Otake, Chiho Omata, Masao Saitoh, Keiji Miyazawa

    Snail is a zinc finger transcription factor encoded by the SNAI1 gene and triggers a cellular process termed epithelial‐mesenchymal transition (EMT) upon its increased expression and/or functional activation. Snail expression and activity are regulated by various extracellular stimuli, including cytokines and environmental factors. Transforming growth factor‐β (TGF‐β) is a Snail inducer that functions via Smad3‐mediated transcriptional activation. In the present study, we identified a distal enhancer that modulates TGF‐β–induced SNAI1 expression. ChIP‐seq and Hi‐C analyses showed that the enhancer is located 46 kb downstream of the SNAI1 gene; in TGF‐β–stimulated cells, it associates with Smad3 and interacts with the SNAI1 proximal promoter. Inhibiting the activity of the enhancer using CRISPRi attenuated TGF‐β–induced SNAI1 expression, stress fiber formation, and cell motility enhancement, suggesting that the enhancer mediates TGF‐β–induced EMT. The enhancer contains a Smad‐binding CAGA motif and an activator protein‐1 (AP‐1) binding motif that function in transcriptional activation. Ras‐responsive element binding protein 1 (RREB1), a transcription factor required for TGF‐β–induced Snail expression, regulated the basal activity of the enhancer but not its inducibility by TGF‐β. In contrast to the enhancer, the association of Smad3 with the proximal promoter was not evident. These findings suggest that the proximal promoter and the distal enhancer respond to distinct signaling cues, integrate them, and cooperatively function to drive SNAI1 expression.


  • Open Access

    Analysis of the DNA ‐binding properties of TGF ‐β‐activated Smad complexes unveils a possible molecular basis for cellular context‐dependent signaling

    by Yuka Itoh, Kunio Miyake, Daizo Koinuma, Chiho Omata, Masao Saitoh, Keiji Miyazawa

    Transforming growth factor‐β (TGF‐β) is a pleiotropic cytokine that modulates a wide variety of cellular responses by regulating target gene expression. It principally transmits signals via receptor‐activated transcription factors Smad2 and Smad3, which form trimeric complexes with Smad4 upon activation and regulate gene expression by binding to genomic DNA. Here, we examined the mechanisms by which TGF‐β regulates the transcription of target genes in a cell context‐dependent manner by screening a double‐stranded DNA oligonucleotide library for DNA sequences bound to endogenous activated Smad complexes. Screening was performed by cyclic amplification of selected targets (CASTing) using an anti‐Smad2/3 antibody and nuclear extracts isolated from three cell lines (A549, HepG2, and HaCaT) stimulated with TGF‐β. The preference of the activated Smad complexes for conventional Smad‐binding motifs such as Smad‐binding element (SBE) and CAGA motifs was different in HepG2 than in the other two cell lines, which may indicate the distinct composition of the activated Smad complexes. Several transcription factor‐binding motifs other than SBE or CAGA, including the Fos/Jun‐binding motifs, were detected in the enriched sequences. Reporter assays using sequences containing these transcription factor‐binding motifs together with Smad‐binding motifs indicated that some of the motifs may be involved in cell type‐dependent transcriptional activation by TGF‐β. The results suggest that the CASTing method is useful for elucidating the molecular basis of context‐dependent Smad signaling.


  • Open Access

    Repression of SMAD3 by STAT3 and c-Ski induces conventional dendritic cell differentiation

    by Jeong-Hwan Yoon, Eunjin Bae, Yasuo Nagafuchi, Katsuko Sudo, Jin Soo Han, Seok Hee Park, Susumu Nakae, Tadashi Yamashita, Ji Hyeon Ju, Isao Matsumoto, et al.

    A pleiotropic immunoregulatory cytokine, TGF-β, signals via the receptor-regulated SMADs: SMAD2 and SMAD3, which are constitutively expressed in normal cells. Here, we show that selective repression of SMAD3 induces cDC differentiation from the CD115+common DC progenitor (CDP). SMAD3 was expressed in haematopoietic cells including the macrophage DC progenitor. However, SMAD3 was specifically down-regulated in CD115+CDPs, SiglecH-pre-DCs, and cDCs, whereas SMAD2 remained constitutive. SMAD3-deficient mice showed a significant increase in cDCs, SiglecH−pre-DCs, and CD115+CDPs compared with the littermate control. SMAD3 repressed the mRNA expression of FLT3 and the cDC-related genes: IRF4 and ID2. We found that one of the SMAD transcriptional corepressors, c-SKI, cooperated with phosphorylated STAT3 at Y705 and S727 to repress the transcription of SMAD3 to induce cDC differentiation. These data indicate that STAT3 and c-Ski induce cDC differentiation by repressing SMAD3: the repressor of the cDC-related genes during the developmental stage between the macrophage DC progenitor and CD115+CDP.


  • Indole-derived compound SIS3 targets a subset of activated Smad complexes

    by Yuka Itoh, Tomoe Sawaguchi, Hao Fu, Chiho Omata, Masao Saitoh, Keiji Miyazawa

    Smad2 and Smad3 are receptor-regulated Smad proteins that transmit signals from cytokines belonging to the transforming growth factor (TGF)-β family, which are vital for adult tissue homeostasis. The overactivation of such proteins often engenders the development of pathological conditions. Smad3 reportedly mediates TGF-β–induced fibrosis. Although various potential Smad3-specific inhibitors are being developed, their specificity and action mechanisms remain largely unknown. This study aimed to establish a biochemical platform to monitor Smad2- or Smad3-dependent TGF-β signaling using SMAD2-, SMAD3-, and SMAD2/3-knockout cell lines alongside TGF-β–dependent luciferase reporters and Smad mutant proteins. Using this platform, SIS3, an indole-derived compound widely used as a specific Smad3 inhibitor, was observed to preferentially suppress a subset of activated Smad complexes. However, its inhibition did not favor Smad3 signaling over Smad2 signaling. These findings indicate that SIS3 can be employed as a probe to examine the heterogeneous nature of Smad signaling that induces gene expression. However, its use as a Smad3-specific inhibitor should be avoided.


  • Open Access

    Smad2Δexon3 and Smad3 have distinct properties in signal transmission leading to TGF-β–induced cell motility

    by Takashi Yokoyama, Takahito Kuga, Yuka Itoh, Shigeo Otake, Chiho Omata, Masao Saitoh, Keiji Miyazawa